Dr. Pollyea Discusses Recent Advances in AML
In Partnership With:
Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia.
Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses recent advances in the treatment landscape of acute myeloid leukemia (AML).
There are have been many recent exciting developments in the AML landscape, says Pollyea. Through the targeted sequencing of patient samples, investigators have begun to better understand the biology of the disease. As a result, targeted therapies have been paired with individual patients’ disease to personalize care.
Other advances include targeting patients based on protein expression and taking advantage of the immune system. There is also the potential to target and eradicate the stem cell population, Pollyea says. Many of these newer approaches are on the horizon, and Pollyea is excited for what is to come for the field of AML.
